Vaishali Pharma Limited VAISHALI NSEPHARMA
Company Overview
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products. In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Why Investors Should Care
Revenue has grown at a 11.0% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.27.
Recent Developments
- Mar 2025 Revenue of ₹97.88 Cr (+19.7% YoY); net profit ₹81.74 L.
- Trailing 12 Months Year-on-year growth — revenue -3.6%, earnings +18.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.0%, profit CAGR -41.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.02% |
| 1 Year: | -3.60% |
Compounded Profit Growth
| 5 Years: | -41.21% |
| 1 Year: | 18.50% |
Stock Price Performance
| 1 Year: | -31.30% |
| 6 Months: | +24.36% |
| 3 Months: | +14.76% |
| 1 Month: | +4.26% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross7d ago
- RSI (14)57.27 · Neutral
P/E of 138.67 is above the sector median of 40.02 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 11.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading at a high P/E of 138.7.
- Earnings shrank at -41.2% CAGR over 5 years.
- Trading 34.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VAISHALI Vaishali Pharma Limited NSEPHARMA | 8.32 | 138.67 | ₹108.54 Cr | 0.00% | 4.72% | 1.26% | 11.02% | -41.21% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,895.00 | 37.64 | ₹4.55 L Cr | 0.85% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,315.00 | 84.60 | ₹2.47 L Cr | 0.31% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,914.00 | 78.62 | ₹1.87 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.23% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA | 688.00 | 237.24 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,156.90 | 23.10 | ₹1.16 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 33.25 | ₹1.12 L Cr | 0.94% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 90.86 | ₹99,417.45 Cr | 0.12% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 |
|---|---|---|
| Revenue | 27.91 Cr | 31.10 Cr |
| Cost of Revenue | 23.74 Cr | 30.64 Cr |
| Gross Profit | 4.18 Cr | 45.76 L |
| Operating Expenses | 2.93 Cr | 32.51 L |
| Operating Income | 1.24 Cr | 13.25 L |
| EBITDA | 2.43 Cr | -4.55 Cr |
| Interest Expense | 38.44 L | 92.60 L |
| Pretax Income | 1.93 Cr | -5.60 Cr |
| Tax Provision | 48.50 L | -1.31 Cr |
| Net Income | 1.44 Cr | -4.29 Cr |
| Diluted EPS | 0.98 | - |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Revenue | 71.54 Cr | 63.82 Cr | 81.76 Cr | 97.88 Cr |
| Cost of Revenue | 63.50 Cr | 54.68 Cr | 74.42 Cr | 85.67 Cr |
| Gross Profit | 8.04 Cr | 9.15 Cr | 7.35 Cr | 12.21 Cr |
| Operating Expenses | 1.56 Cr | 17.50 L | 1.01 Cr | 6.31 Cr |
| Operating Income | 6.48 Cr | 8.97 Cr | 6.34 Cr | 5.90 Cr |
| EBITDA | 8.67 Cr | 11.61 Cr | 3.70 Cr | 3.78 Cr |
| Interest Expense | 2.49 Cr | 2.26 Cr | 2.27 Cr | 2.07 Cr |
| Pretax Income | 5.73 Cr | 8.85 Cr | 92.61 L | 1.23 Cr |
| Tax Provision | 1.70 Cr | 2.24 Cr | 20.72 L | 40.84 L |
| Net Income | 4.02 Cr | 6.60 Cr | 71.89 L | 81.74 L |
| Diluted EPS | 0.38 | 0.59 | 0.07 | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Total Assets | 81.62 Cr | 78.90 Cr | 79.96 Cr | 109.84 Cr |
| Current Assets | 76.43 Cr | 72.67 Cr | 74.52 Cr | 104.48 Cr |
| Cash & Equivalents | 1.16 Cr | 52.91 L | 1.46 Cr | 1.71 Cr |
| Inventory | 62.90 L | 3.05 Cr | 37.97 L | 4.81 Cr |
| Receivables | 58.51 Cr | 53.61 Cr | 49.43 Cr | 46.72 Cr |
| Total Liabilities | 55.27 Cr | 38.37 Cr | 37.12 Cr | 44.93 Cr |
| Current Liabilities | 51.94 Cr | 32.07 Cr | 33.08 Cr | 40.05 Cr |
| Long Term Debt | 3.11 Cr | 5.23 Cr | 3.60 Cr | 4.20 Cr |
| Total Debt | 20.81 Cr | 14.74 Cr | 13.49 Cr | 12.32 Cr |
| Total Equity | 26.35 Cr | 40.53 Cr | 42.84 Cr | 64.92 Cr |
| Shares Outstanding | 10.55 Cr | 10.55 Cr | 10.72 Cr | 13.05 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 1.32 Cr | 1.08 Cr | 80.67 L | -18.04 Cr |
| Investing Cash Flow | -84.68 L | 28.21 L | 1.20 Cr | -18.81 L |
| Financing Cash Flow | 41.75 L | -1.73 Cr | -1.42 Cr | 18.49 Cr |
| Capital Expenditure | -86.48 L | -29.72 L | -11.10 L | -30.46 L |
| Free Cash Flow | 45.38 L | 78.24 L | 69.57 L | -18.34 Cr |
| Net Change in Cash | 88.93 L | -37.05 L | 59.36 L | 26.47 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Gross Margin % | 11.2% | 14.3% | 9.0% | 12.5% |
| Operating Margin % | 9.1% | 14.1% | 7.8% | 6.0% |
| Net Margin % | 5.6% | 10.3% | 0.9% | 0.8% |
| ROE % | 15.3% | 16.3% | 1.7% | 1.3% |
| ROCE % | 21.8% | 19.2% | 13.5% | 8.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VAISHALI
Buy or sell: Gift Nifty hints cautious start | Vaishali Parekh recommends three stocks to buy today - 3 September 2026 - TradingView
<a href="https://news.google.com/rss/articles/CBMi_wFBVV95cUxPbWV5a3JvVHlFVzYzbkxJZV9hc1dSM01OSTJ0S3NDcHR2QmxfdXhDM3BReTR6aERZeTlWd1E4WGlYMWhPWjdOck80YkdndERWYUE4cG1aMkN6UlRFS2QwRm8zSVBVaWFzRUVxM3U4RmlnZFVVeElqUkh2X05mTkhwZEFqSW5fbGNfU294cV…
Stocks to buy under Rs.100: Vaishali Parekh recommends three stocks to buy or sell - TradingView
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxQSEZRRUdoY1B1dmV5NTNZLWoyLUhkN3NlRk90OFZhZjNuYmROUm0zYmVnN2FZQlRVdC1vSnFpcTREbVZXR281RU9kRFhZSUpBLVF3U1p5TV85cmFMZ3NBM2ROX1daTmg0WDFMR3dlakpLQmlObE11bHNXc3lTcTJ4ZlQ1QWlLWjhMMHQ2Ml…
ATI (ATI) SVP Bhatia has 3,509 shares withheld to cover RSU taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOZkN4UjNuc3dJTWFTMDJxZnl1RlAyUmxrVFNDdFZqOExZblJuUUxHVTZlQWo3Ty1keElCbThEUS0wc3VOTTFjLW82X05iZ0g0bkVJcFh0Y3pQRFhKblU3aTQ4ZDNzNzNzd190MTFfcnlUSWdIZGlCY2d3UTV2aWxrOHNGX3A1a0t4N1BPZE…
Vaishali Parkar Kumar acquires 1.9 lakh Rose Merc shares via ESOP - scanx.trade
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNbHRKT01tTGdzeGlpbGRNUDhEMGRmMVQyWnZ2aGxZWWlNSVhNc29tT0lTSnotT291RVdnemk0TVhmLWtwU2g1M3RUeU50bjJPQXRYUnNLZTBOSHRJSktBMFVMS2NxQndTZUlDNEtXVXdRS1V1UXdiWW1mT1hfMndpWjFMQmhLcDlMWDVQZ3…
Nifty Rally Gets A Boost From Falling Oil: Vaishali Parekh On What Comes Next - Business Today
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxOY1Z6aWFURUZzZ2doVHJxdVg5N0NhNHpBb29BbnpndUEwRnZPMzFTd05KZlpBZjU0VmMwUWxWY2s3cE92U2RSSjdBV1AzYkw3RDJILUhQaVo0VVBCaXlibUFjbjNmVjkxalVhelB5NGpRWU5FbjI0a3k0b0Z1d25wWjBncjVyUEE3NXUySX…
Vaishali Pharma Slightly Declines as Stock Hovers Near Support Levels - Golden Cross - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNbm5Cby1PT0FRc2RLU295WFM4aVZvX052TUlFX19sdS1WNThMWDRBbTYzb3VBNnBVYi1IVTFJRFV0bGowUU1pb01uVWZTNzZnUU4tbWxocEZjRDB6X1pZY2NJb2pTdUJmY21mYmUxZlZ5Wlh2U3Q5T3p3VTVwU0RKTG1td1hTNURQMXBPMl…
VAISHALI — Frequently Asked Questions
What is the current share price of Vaishali Pharma Limited (VAISHALI)?
As of 2026-09-20 09:43 IST, Vaishali Pharma Limited (VAISHALI) trades at ₹8.32 on NSE. Its 52-week range is ₹4.88 to ₹12.66.
What is the market capitalisation of VAISHALI?
Vaishali Pharma Limited (VAISHALI) has a market capitalisation of ₹108.54 Cr on NSE.
What is the P/E ratio of VAISHALI?
VAISHALI trades at a trailing price-to-earnings (P/E) ratio of 138.67. The industry average P/E is 40.02. Its price-to-book (P/B) ratio is 1.54.
What is the return on equity (ROE) of VAISHALI?
VAISHALI has a return on equity (ROE) of 1.26%. Its return on capital employed (ROCE) is 4.72%.
Is VAISHALI a good stock to buy?
This page provides a data-driven analysis of Vaishali Pharma Limited (VAISHALI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.